Hypoxia Stress Response Pathways: Modeling and Targeted Therapy

Hypoxia is a consequence of the decrease in the oxygen reaching the tissues of the body. It is a prominent feature of most solid tumors and is known to promote malignant progression, metastatic capacity, resistance to chemotherapy, and leads to poor patient prognosis. When a cell is under hypoxic stress, a cascade of cell signals is initiated through a family of transcription factors named as hypoxia inducible factors (HIFs). During hypoxia, HIF stabilizes and enters the nucleus and binds to the DNA via the hypoxia response element (HRE) and leads to the translation of downstream genes. The decision of adaptation or cell death depends on the extent of hypoxic stress faced by the cells. Proper understanding of hypoxic stress response is critical for understanding the mechanism of tumor cell adaptation to hypoxia and to develop efficient therapeutic interventions. In this paper, we develop a Boolean network model with targeted drug intervention in a cell that mimics persistent hypoxia. This hypoxic pathway is combined with pathways that help the cell adapt to the situation or undergo cell death. It is linked to apoptosis, cell survival, and energy production via the p53/Mdm2, PI3k/Akt/mTOR, and Glycolysis/TCA cycle pathways, respectively. In this model, we have incorporated eight known anticancer drugs that target these pathways. Through simulations, we have identified drug combinations that provided overall benefits to the cell in comparison to the no intervention case. Where applicable, the behavior predicted by this model is in agreement with experimental observations from the published literature.

[1]  C. Andreani,et al.  Dorsomorphin reverses the mesenchymal phenotype of breast cancer initiating cells by inhibition of bone morphogenetic protein signaling. , 2014, Cellular signalling.

[2]  Shailendra Giri,et al.  Discrete mechanisms of mTOR and cell cycle regulation by AMPK agonists independent of AMPK , 2014, Proceedings of the National Academy of Sciences.

[3]  P. Goodwin,et al.  Understanding the benefit of metformin use in cancer treatment , 2011, BMC medicine.

[4]  Aleksander S. Popel,et al.  Reactive Oxygen Species Regulate Hypoxia-Inducible Factor 1α Differentially in Cancer and Ischemia , 2008, Molecular and Cellular Biology.

[5]  G. Semenza,et al.  HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. , 2006, Cell metabolism.

[6]  J. Mackey,et al.  Dichloroacetate (DCA) as a potential metabolic-targeting therapy for cancer , 2008, British Journal of Cancer.

[7]  Bin Xu,et al.  Colorectal Cancer Cells Refractory to Anti-VEGF Treatment Are Vulnerable to Glycolytic Blockade due to Persistent Impairment of Mitochondria , 2013, Molecular Cancer Therapeutics.

[8]  G. Melillo,et al.  Inhibiting Hypoxia-Inducible Factor 1 for Cancer Therapy , 2006, Molecular Cancer Research.

[9]  W. Wilson,et al.  Targeting hypoxia in cancer therapy , 2011, Nature Reviews Cancer.

[10]  R. Weinmann,et al.  Enhancer element at the 3'-flanking region controls transcriptional response to hypoxia in the human erythropoietin gene. , 1991, The Journal of biological chemistry.

[11]  Joon Young Choi,et al.  Synergistic Anti-Cancer Effect of Phenformin and Oxamate , 2014, PloS one.

[12]  Alfonso Bellacosa,et al.  Epithelial–mesenchymal transition in development and cancer: role of phosphatidylinositol 3′ kinase/AKT pathways , 2005, Oncogene.

[13]  Murtaza M Tambuwala,et al.  A dynamic model of the hypoxia-inducible factor 1&agr; (HIF-1&agr;) network , 2013, Journal of Cell Science.

[14]  G. Semenza,et al.  Temporal, spatial, and oxygen-regulated expression of hypoxia-inducible factor-1 in the lung. , 1998, The American journal of physiology.

[15]  Aniruddha Datta,et al.  Introduction to Genomic Signal Processing with Control , 2006 .

[16]  J. Lévesque,et al.  Targeting the Hypoxia‐Sensing Pathway in Clinical Hematology , 2014, Stem cells translational medicine.

[17]  C. Hoppel,et al.  Ischemic defects in the electron transport chain increase the production of reactive oxygen species from isolated rat heart mitochondria. , 2008, American journal of physiology. Cell physiology.

[18]  S. Choe,et al.  BMPs and their clinical potentials. , 2011, BMB reports.

[19]  Aniruddha Datta,et al.  From biological pathways to regulatory networks , 2010, CDC.

[20]  Michael I. Wilson,et al.  C. elegans EGL-9 and Mammalian Homologs Define a Family of Dioxygenases that Regulate HIF by Prolyl Hydroxylation , 2001, Cell.

[21]  G. Semenza Targeting HIF-1 for cancer therapy , 2003, Nature Reviews Cancer.

[22]  R. Bristow,et al.  Tumor hypoxia as a driving force in genetic instability , 2013, Genome Integrity.

[23]  Mire Zloh,et al.  Targeting Glycolysis: A Fragment Based Approach Towards Bifunctional Inhibitors of hLDH-5. , 2011 .

[24]  G. Semenza,et al.  Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[25]  S. Colowick,et al.  The role of glycolysis in the growth of tumor cells. II. The effect of oxamic acid on the growth of HeLa cells in tissue culture. , 1961, The Journal of biological chemistry.

[26]  G. Powis,et al.  Hypoxia inducible factor-1alpha as a cancer drug target. , 2004, Molecular cancer therapeutics.

[27]  P. Schumacker,et al.  Mitochondrial complex III is required for hypoxia-induced ROS production and cellular oxygen sensing. , 2005, Cell metabolism.

[28]  Xin Yu,et al.  3-Bromopyruvic acid, a hexokinase II inhibitor, is an effective antitumor agent on the hepatoma cells : in vitro and in vivo findings. , 2014, Anti-cancer agents in medicinal chemistry.

[29]  M. Roizen,et al.  Hallmarks of Cancer: The Next Generation , 2012 .

[30]  Steven O Simmons,et al.  Cellular stress response pathway system as a sentinel ensemble in toxicological screening. , 2009, Toxicological sciences : an official journal of the Society of Toxicology.

[31]  Debby Laukens,et al.  Pharmacologic activation of tumor hypoxia: a means to increase tumor 2-deoxy-2-[18F]fluoro-D-glucose uptake? , 2013, Molecular imaging.

[32]  Mark A. Schroeder,et al.  Targeting Src Family Kinases Inhibits Bevacizumab-Induced Glioma Cell Invasion , 2013, PloS one.

[33]  N. Denko,et al.  Hypoxia, HIF1 and glucose metabolism in the solid tumour , 2008, Nature Reviews Cancer.

[34]  Giuseppe Cicero,et al.  Hypoxia and Human Genome Stability: Downregulation of BRCA2 Expression in Breast Cancer Cell Lines , 2013, BioMed research international.

[35]  Marianne Koritzinsky,et al.  Translational control of gene expression during hypoxia , 2006, Cancer biology & therapy.

[36]  P. ten Dijke,et al.  BMP signaling in vascular diseases , 2012, FEBS letters.

[37]  G. Semenza,et al.  HIF-1 and human disease: one highly involved factor. , 2000, Genes & development.

[38]  A. Datta,et al.  Boolean modeling and fault diagnosis in oxidative stress response , 2012, BMC Genomics.

[39]  A. Levine,et al.  The Control of the Metabolic Switch in Cancers by Oncogenes and Tumor Suppressor Genes , 2010, Science.

[40]  N. Chandel,et al.  Reactive Oxygen Species Generated at Mitochondrial Complex III Stabilize Hypoxia-inducible Factor-1α during Hypoxia , 2000, The Journal of Biological Chemistry.